ANTIBODIES THAT BIND TO PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) Russian patent published in 2019 - IPC C07K16/28 

FIELD: biotechnology.

SUBSTANCE: invention relates to isolated antibodies which specifically bind to human PD-L1 and contain three CDR light chain: CDRL1, CDRL2 and CDRL3, and three heavy chain CDRs: CDRH1, CDRH2 and CDRH3, where CDRL1 is SEQ ID NO: 9, CDRL2 is SEQ ID NO: 2, CDRL3 is SEQ ID NO: 10, CDRH1 is SEQ ID NO: 14 or SEQ ID NO: 15, CDRH2 is SEQ ID NO: 16 and CDRH3 is SEQ ID NO: 17 or CDRL1 is SEQ ID NO: 21, CDRL2 is SEQ ID NO: 2, CDRL3 is SEQ ID NO: 22, CDRH1 is SEQ ID NO: 26, CDRH2 is SEQ ID NO: 28 and CDRH3 is SEQ ID NO: 29, as well as to antigen-binding fragments of such antibodies. Disclosed are nucleic acid molecules encoding antibodies and antigen-binding fragments of the present invention, as well as expression vectors and host cells for expression thereof, a method for analyzing expression of human PD-L1 in a human tissue sample. Disclosed is a kit for detecting a complex of an antibody or an antigen-binding fragment bound to human PD-L1, and a diagnostic antibody composition for detecting PD-L1 expression.

EFFECT: invention widens the range of agents for detecting PD-L1 expression.

15 cl, 11 dwg, 5 tbl, 3 ex